Kirby McInerney LLP is reminding investors that the deadline to apply for the position of lead plaintiff in a federal securities class action against BioAge Labs, Inc. (NASDAQ: BIOA) is rapidly approaching—March 10, 2025. The action pertains to those who purchased BioAge securities between September 22, 2024, and January 7, 2025, known as the “Class Period.”
BioAge Labs, which went public through an initial public offering (IPO) on September 27, 2024, offered 12.65 million shares at $18 each. The IPO raised significant attention due to the company’s collaboration with Eli Lilly and Company, particularly its involvement in the STRIDES clinical trial for BioAge’s primary product candidate, azelaprag. The clinical trial was designed to evaluate the combination of azelaprag and GLP-IR agonists for potential weight loss benefits.
The situation dramatically changed when, just a few months after the IPO, BioAge announced the termination of the STRIDES Phase 2 trial on December 6, 2024. This decision was made due to emerging safety concerns, specifically liver transaminitis in participants.
Following this news, BioAge’s stock price suffered a significant drop of approximately 76%, falling from a closing price of $20.09 on December 6, 2024, to $4.65 on December 9, 2024, reflecting a loss of $15.44 per share. The complaint against BioAge Labs alleges that the company and its affiliates made false or misleading statements about the STRIDES Phase 2 clinical trial in the IPO documents and throughout the Class Period.
Investors who purchased or acquired BioAge securities, or possess relevant information, are encouraged to contact Thomas W. Elrod of Kirby McInerney LLP at investigations@kmllp.com or fill out the form.
BioAge Labs is a biotechnology company dedicated to extending healthy human lifespan by developing therapeutics that target the biological mechanisms of aging. The company leverages its proprietary platform, which integrates data from human aging biology with advanced machine learning, to identify novel drug candidates for age-related diseases. BioAge’s approach focuses on aging biomarkers to accelerate drug discovery, aiming to improve healthspan by targeting the molecular pathways that drive aging. Founded by a team of experts in biology, chemistry, and drug development, BioAge is committed to advancing therapeutics that can delay or even reverse the aging process, contributing to longer, healthier lives.
Kirby McInerney LLP, founded in 1996 and based in New York, is a leading law firm specializing in securities fraud, class actions, and complex litigation. The firm represents institutional and individual clients in federal and state courts, focusing on protecting investors' rights. Known for its success in high-stakes cases, Kirby McInerney has secured substantial recoveries for clients in securities fraud and financial disputes, earning a strong reputation for its expertise and results.
